Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment.

Scheggia D, Mastrogiacomo R, Mereu M, Sannino S, Straub RE, Armando M, Managò F, Guadagna S, Piras F, Zhang F, Kleinman JE, Hyde TM, Kaalund SS, Pontillo M, Orso G, Caltagirone C, Borrelli E, De Luca MA, Vicari S, Weinberger DR, Spalletta G, Papaleo F.

Nat Commun. 2018 Jun 11;9(1):2265. doi: 10.1038/s41467-018-04711-w. Erratum in: Nat Commun. 2018 Aug 29;9(1):3560.

2.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
3.

Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia.

Chen Y, Bang S, McMullen MF, Kazi H, Talbot K, Ho MX, Carlson G, Arnold SE, Ong WY, Kim SF.

Mol Neurobiol. 2017 Apr;54(3):1699-1709. doi: 10.1007/s12035-016-9773-x. Epub 2016 Feb 12.

4.

Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.

Nørbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L, Allerup PN, Rostrup E, Pinborg LH, Glenthøj BY.

Int J Neuropsychopharmacol. 2016 Apr 29;19(5). pii: pyw006. doi: 10.1093/ijnp/pyw006. Print 2016 May.

5.

Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways.

Papaleo F, Yang F, Garcia S, Chen J, Lu B, Crawley JN, Weinberger DR.

Mol Psychiatry. 2012 Jan;17(1):85-98. doi: 10.1038/mp.2010.106. Epub 2010 Oct 19.

6.

Dysbindin-1 Involvement in the Etiology of Schizophrenia.

Wang H, Xu J, Lazarovici P, Zheng W.

Int J Mol Sci. 2017 Sep 22;18(10). pii: E2044. doi: 10.3390/ijms18102044. Review.

7.

Single point mutation on the gene encoding dysbindin results in recognition deficits.

Chang EH, Fernando K, Yeung LWE, Barbari K, Chandon TS, Malhotra AK.

Genes Brain Behav. 2018 Jun;17(5):e12449. doi: 10.1111/gbb.12449. Epub 2018 Jan 11.

PMID:
29227583
8.

Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.

Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó V, Lluis C, Franco R, García-Sevilla JA, Meana JJ.

Psychopharmacology (Berl). 2009 Oct;206(2):313-24. doi: 10.1007/s00213-009-1608-2. Epub 2009 Aug 4.

PMID:
19652957
9.

Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus.

Chiba S, Hashimoto R, Hattori S, Yohda M, Lipska B, Weinberger DR, Kunugi H.

J Neural Transm (Vienna). 2006 Sep;113(9):1337-46. Epub 2006 Feb 6.

PMID:
16463116
10.

Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.

Marcus MM, Björkholm C, Malmerfelt A, Möller A, Påhlsson N, Konradsson-Geuken Å, Feltmann K, Jardemark K, Schilström B, Svensson TH.

Eur Neuropsychopharmacol. 2016 Sep;26(9):1401-1411. doi: 10.1016/j.euroneuro.2016.07.004. Epub 2016 Jul 26.

PMID:
27474687
11.

Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia.

Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC, Graff-Guerrero A.

Am J Geriatr Psychiatry. 2017 Jan;25(1):1-10. doi: 10.1016/j.jagp.2016.08.001. Epub 2016 Aug 2.

12.

Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain.

Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, Herman MM, Weinberger DR, Kleinman JE.

Arch Gen Psychiatry. 2004 Jun;61(6):544-55.

PMID:
15184234
13.

Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance.

Karlsgodt KH, Robleto K, Trantham-Davidson H, Jairl C, Cannon TD, Lavin A, Jentsch JD.

Biol Psychiatry. 2011 Jan 1;69(1):28-34. doi: 10.1016/j.biopsych.2010.09.012. Epub 2010 Oct 30.

14.

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.

JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891.

PMID:
26131622
15.

Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia.

Konopaske GT, Balu DT, Presti KT, Chan G, Benes FM, Coyle JT.

Schizophr Res. 2018 Nov;201:270-277. doi: 10.1016/j.schres.2018.04.042. Epub 2018 May 11.

PMID:
29759351
16.

Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.

Sanyal S, Van Tol HH.

J Psychiatr Res. 1997 Mar-Apr;31(2):219-32. Review.

PMID:
9278187
17.

An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers.

Murphy A, Dursun S, McKie S, Elliott R, Deakin JF.

Psychopharmacology (Berl). 2016 Apr;233(8):1415-26. doi: 10.1007/s00213-016-4234-9. Epub 2016 Feb 22.

18.

The puzzle box as a simple and efficient behavioral test for exploring impairments of general cognition and executive functions in mouse models of schizophrenia.

Ben Abdallah NM, Fuss J, Trusel M, Galsworthy MJ, Bobsin K, Colacicco G, Deacon RM, Riva MA, Kellendonk C, Sprengel R, Lipp HP, Gass P.

Exp Neurol. 2011 Jan;227(1):42-52. doi: 10.1016/j.expneurol.2010.09.008. Epub 2010 Sep 17.

PMID:
20851119
19.

Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Bishop JR, Reilly JL, Harris MS, Patel SR, Kittles R, Badner JA, Prasad KM, Nimgaonkar VL, Keshavan MS, Sweeney JA.

Psychopharmacology (Berl). 2015 Jan;232(1):145-54. doi: 10.1007/s00213-014-3649-4. Epub 2014 Aug 7.

20.

Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.

Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A.

Psychopharmacology (Berl). 2004 Oct;175(4):473-80.

PMID:
15083259

Supplemental Content

Support Center